{"id":"NCT02545075","sponsor":"Bristol-Myers Squibb","briefTitle":"A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine","officialTitle":"A Randomized, Open-Label, Two-arm, Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-31","primaryCompletion":"2019-04-19","completion":"2019-04-19","firstPosted":"2015-09-09","resultsPosted":"2020-05-19","lastUpdate":"2020-05-19"},"enrollment":182,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"Ipilimumab","otherNames":["MDX-010"]},{"type":"DRUG","name":"Dacarbazine","otherNames":["DTIC"]}],"arms":[{"label":"Ipilimumab","type":"EXPERIMENTAL"},{"label":"Dacarbazine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.","primaryOutcome":{"measure":"Two-Years Survival Rate","timeFrame":"24 months","effectByArm":[{"arm":"Ipilimumab (3 mg/kg)","deltaMin":33.98,"sd":null},{"arm":"Dacarbazine (250 mg/m2)","deltaMin":34.09,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5059"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":8,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://www.bmsstudyconnect.com/s/US/English/USenHome","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":122},"commonTop":["Alanine aminotransferase increased","Decreased appetite","Nausea","Aspartate aminotransferase increased","Rash"]}}